Different dosing intervals of mifepristone-misoprostol for second-trimester termination of pregnancy: A meta-analysis and systematic review

Int J Gynaecol Obstet. 2021 Aug;154(2):195-203. doi: 10.1002/ijgo.13541. Epub 2021 Jun 8.

Abstract

Objective: To compare 1- and 2-day drug administration interval between mifepristone and misoprostol for second-trimester pregnancy termination and provide evidence-based recommendations.

Methods: Search strategy: the search was performed in Pubmed, EMBASE, and Cochrane Library for the relevant published studies from their establishment to March 2020.

Selection criteria: randomized controlled trials (RCTs) comparing 1- and 2-day time interval of mifepristone-misoprostol for termination of pregnancy during second-trimester pregnancy were considered. Data were processed using Revman 5.3 software.

Results: Meta-analyses of three RCTs showed no significant difference was reported in the induction-to-abortion time and successful abortion rate between 1- and 2-day mifepristone and misoprostol intervals. Statistical difference was not identified in the induction-to-abortion time between the two drug administration intervals in nulliparous or parous women.

Conclusions: Both 1- and 2-day dosing intervals between mifepristone and misoprostol are suitable for clinical use for second-trimester medical termination of pregnancy.

Keywords: medical abortion; mifepristone; misoprostol; second pregnancy trimester.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Abortifacient Agents / administration & dosage
  • Abortifacient Agents, Nonsteroidal / administration & dosage
  • Abortion, Induced* / methods
  • Female
  • Humans
  • Mifepristone* / administration & dosage
  • Misoprostol* / administration & dosage
  • Pregnancy
  • Pregnancy Trimester, Second
  • Randomized Controlled Trials as Topic

Substances

  • Abortifacient Agents
  • Abortifacient Agents, Nonsteroidal
  • Mifepristone
  • Misoprostol